Skip to content
2000
Volume 9, Issue 12
  • ISSN: 0929-8673
  • E-ISSN: 1875-533X

Abstract

Serotonin N-acetyltransferase (arylalkylamine N-acetyltransferase, AANAT) catalyzes the rate-limiting step in the biosynthesis of the circadian hormone melatonin from serotonin. Although melatonin was identified 40 years ago, relatively little is known about its (patho)physiological roles, and a solid scientific foundation is still lacking for most therapeutic applications currently claimed for melatonin. The development of potent, specific, and cell permeable inhibitors for AANAT should constitute an important strategy to address these issues. These inhibitors are also potential therapeutics for various sleep / mood disorders. This review will focus on the efforts toward developing in vitro and in vivo AANAT inhibitors, including basic mechanistic studies on AANAT, which have played an important role in design.

Loading

Article metrics loading...

/content/journals/cmc/10.2174/0929867023370013
2002-06-01
2025-04-09
Loading full text...

Full text loading...

/content/journals/cmc/10.2174/0929867023370013
Loading

  • Article Type:
    Review Article
Keyword(s): aanat; aanat inhibitor; mood disorder; serotonin n-acefyltransferase; sleep disorder
This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error
Please enter a valid_number test